Scroll To Top
Search by Speciality


Prague Congress Centre (PCC) * | Prague, CZECH REPUBLIC
From 230 to 600 EUR
Event Preview
This event
is Finished
Specialty: Clinical Pharmacology
Dates: From Nov, 22, 2017 to Nov, 24, 2017
Location: Prague, CZECH REPUBLIC
Type: Conference
Registration Cost: From 230 to 600 EUR
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for PRAGUE, Czech republic.
General Info
Event Venue:

Prague Congress Centre (PCC) *

Did you know that the Prague Congress Centre boasts a hall which ranks 13th in the world for best acoustics?      With beautiful panoramic views over the city, the Prague Congress Centre (PCC) is one of the most prominent landmarks of the Czech capital. The PCC complex also includes the Vyšehrad Business Centre and the 4-star Holiday Inn Prague Congress Centre with 251 rooms. The Prague Congress Centre ranks among the best-known congress venues in Europe with more than 50 halls, reception and meeting rooms with a total capacity of up to 9,300 people, and 13,000 m of exhibition space. The centre’s high technical standards and diverse options for arranging meeting spaces make the venue a prime choice for hosting exhibitions, social events, banquets, and cultural productions, as well as congresses and conferences. The largest hall is the Congress Hall with a maximum capacity of 2,764. Thanks to its excellent acoustics, the Congress Hall ranks among the best concert halls in the world. The Prague Congress Centre has hosted a number of high-profile international conferences and gatherings: 2000  Annual Meeting of the Boards of Governors of the International Monetary Fund (IMF) and World Bank 2002 NATO Summit 2009 All major conferences and meetings hosted by the Czech Republic when holding the Presidency of the Council of the European Union 2014 ICM Prague 2014 - The 30th Triennial Congress on the International Confederation of Midwives (3,000 attendees) 2013 AMEE - Association for Medical Education in Europe (3000 attendees) 2012 EADV – European Academy of Dermatology and Venereology Congress “Skin is vital”  (8,000 attendees) 2011 ERA-EDTA – European Renal Association – European Dialysis and Transplant Association (8,000 attendees) 2008 WPA – World Congress of Psychiatry (5,500 attendees) 2006 ESHRE – European Society of Human Reproduction and Embryology Click here for an overview of other past events
Visit the Venue to read more



European Accreditation Council for Continuing Medical Education (UEMS/EACCME)

An application will be made to the European Accreditation Council for Continuing Medical Education (EACCM​E) for CME accreditation of this event. The EACCME is an institution of the European Union of Medical Specialists (UEMS):

American Medical Association (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at​.

Royal College of Physicians and Surgeons of Canada

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit:​. ​​​​


Kenes is committed to being a valuable and knowledgeable partner in the design and delivery of educationally strong, independent, transparent, and effective CME/CPD programs. Kenes is a proud member of the Good CME Practice Group (gCMEp), a member organization contributing to improving health outcomes by:


Championing best practice in CME/CPD

Maintaining and improving standards

Mentoring and educating

Working in collaboration with critical stakeholders

Membership in the Good CME Practice Group illustrates the Kenes commitment to high standards and knowledgeable partnership with its clients in the design and delivery of educationally strong, independent, transparent, effective and financially viable medical events.​​

Concerned Audience:
  • Medical_Professionals
  • Medical_students
  • Nurses
Event Overview
Welcome message:

Dear Colleagues, Friends, Partners and Supporters,

The second International Conference on Medical Cannabis and Cannabinoids will be held in Prague, Czech Republic, on November 22-24, 2017. The main aim of the conference is to bring the latest information and best practices on the introduction of medical cannabis into modern evidence-based medicine and to help to establish the use of medical cannabis as a standard medical procedure worldwide. 

One of the important goals of the 2017 International Medical Cannabis and Cannabinoids Conference is to review the effectiveness of different national and state-based legal approaches allowing medical cannabis and related products in the broader context of a global regulatory regime on psychotropic pharmaceuticals that has created legal, logistical, and economic barriers to their availability to people in indisputable need of them. 

The conference aims to bring together cutting-edge researchers and scientists in the field of medical cannabis and cannabinoids, in regulatory and political science, in health economics, and in translational science. We want to raise overall media and political awareness about the current benefits and the clearly huge potential of the medical use of cannabis and cannabinoids, and, similarly to our 2015 conference, we will provide a broad and comfortable platform for the strengthening and better coordination of the global movement of patients who can benefit from the use of medical cannabis. 

We are aware of the growing business opportunities in the area of medical cannabis and we acknowledge the importance of responsible entrepreneurship in this quickly developing and extremely promising field. Thus, we provide networking venues and arranged meetings for representatives of industry and other key players in the field. 

Finally, we will provide discussion forum and workshops for policy makers, scientists, medical professionals and their patients, and other involved groups where the novel and/or controversial issues in the field should be raised and debated. A rich social programme will be complemented by several educational side events prepared in cooperation with academic institutions.

The event is organised jointly by the research and education institute ResAd and the global conference organiser KENES. It is supported by the International Society for Studies of Drug Policy, European Monitoring Centre for Drugs and Drug Addiction, the Global Commission on Drug Policy, Czech Medical Academy, Czech Medical Society for Cannabis and Cannabinoids Treatment and Its Research, and others.

Our conference is another step towards lege artis use and safe access to medical cannabis in modern society. 

We are looking forward to meeting you in Prague!



Ben Bronfman first became interested in the cannabis space seven years ago when he moved to Los Angeles, CA. After surveying the industry, he decided to join the board of Americans for Safe Access. At that time there were 16 States which had passed Cannabis laws. Mr. Bronfman has been one of ASA’S most engaged board members. In addition to his work with ASA, Bronfman partnered with various Silicon Valley investors to help elect Kamala Harris, The Attorney General of California, who was locked in a standoff election with Steve Cooley in 2010. This helped ensure that the laws in the country’s largest cannabis market would not be reversed.

Mr. Bronfman is an entrepreneur, environmentalist and Grammy-nominated musician/producer based in New York City. Mr. Bronfman is managing director of Global Thermostat, which he co- founded with Columbia University economist Graciela Chichilinsky and fellow Columbia Professor Peter Eisenberger. Mr Bronfman was responsible for securing the firm’s $100M valuation and has orchestrated various business and strategic partnerships for the firm.  Bronfman is on the board of several organizations including Pioneer Works, a center for art and innovation in Red Hook, Brooklyn.. Mr. Bronfman also has positions in various technology start ups and was recently the recipient of Global Green’s impact Entrepreneur Award alongside the Clinton Foundation. 


Dr. Allan I. Frankel is one of the World’s leading authorities on Dosed Cannabis

Medicine. With over 37 years experience in Internal Medicine, Dr. Frankel applies his knowledge of all aspects of the Cannabis plant, and its therapeutic value as a dosed medicine. He established GreenBridge Medical, Inc. in 2007 to provide the highest quality medical treatment to patients suffering from multiple chronic and serious medical conditions.

Dr. Frankel has presented multiple CME accredited Grand Round Lectures on

Internal Medicine and Therapies in Medical Cannabis and participated in round

table discussions on the topic of future therapies and research for Medical Cannabis sponsored by the California Medical Association and the Los Angeles County Medical Association. He has also been a featured speaker on medical cannabis therapies at the International Pelvic Pain Society conference, The University of Washington, Cedars-Sinai Hospital and numerous support groups and care facilities.

Dr. Frankel developed the Chartscape medical software program used by the UCLA Bowyer Cancer Center, the eScript medical software utilized by Kaiser Permanente Health System, is the founder of GreenlifeDocs and the CEO of GreenBridge Medical Services.

Dr. Frankel graduated second in his class from the UCLA School of Medicine where he was elected to the Alpha Omega Alpha medical honors society. For three years Dr. Frankel was selected by his peers as one of the Top Internists in LA. He was also a Clinical Professor for eighteen years for the University of California Los Angeles School of Medicine.

Dr. Frankel lives in Los Angeles, California, has a daughter, two sons, five grandsons and a granddaughter.


Lumír Ondřej Hanuš obtained his M.S. in analytical chemistry (1972), Ph.D. in analytical chemistry (1974) and associate professor in organic chemistry (1994) from Palacký University (Olomouc, Czech Republic) and his D.Sc. in pharmaceutical chemistry (1995) from Charles University (Prague, Czech Republic). Between years 1971 and 1990 did research and teached at Medical Faculty, Palacký University (Olomouc). Period 1978–1979 spent as research associate at School of Pharmacy, University of Mississippi, USA. From 1990 up to present time (as researcher, professor haver, and Research Fellow) is with School of Pharmacy (Hebrew University, Jerusalem, Israel). Between years 1997 and 1998 was visiting associate (NIDDK, NIH, Bethesda, USA) and in 2001–2002 as research fellow at NIAAA (NIH, Bethesda, USA). At present time, he is Research Fellow of Hebrew University in Jerusalem. He was awarded with Honorary Doctorate degree - Chemiae Doctor honoris causa (2007) and Medicinae Doctor honoris causa (2011), Hanuš medal (2005), Addictology Award (2012), and Olomouc City Award (2013).


Brendan Hughes has been working at EMCDDA since 2001 in the field of national drug legislation, after gaining a Masters degree in International Criminal Law (LLM) specialising in narcotics law. He manages the European Legal Database on Drugs (ELDD) which holds various comparative overviews and analyses on different topics relevant to drug laws; not only use, possession and trafficking laws, but also issues such as drug classifications, threshold quantities, alternatives to punishment, drug driving, procedures for classifying new substances as drugs, and regulatory frameworks for substitution treatment. He published the first European quantitative comparison of drug law sentencing and outcome statistics in 2009, and is currently working on a pilot index for comparing drug laws across countries and over time. 


Michel D. Kazatchkine was Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2007 to 2012. The Global Fund, based in Geneva, Switzerland, is the world’s leading multilateral financier of programs for the three diseases and one of the major financiers of health systems strengthening. In 2012, then UN Secretary-General Ban Ki-Moon appointed him as United Nations Special Envoy for HIV/AIDS in Eastern Europe and Central Asia.

Dr Kazatchkine has spent the past 25 years fighting AIDS as a leading physician, researcher, administrator, advocate, policy maker, and diplomat. He attended medical school at Necker-Enfants-Malades in Paris, studied immunology at the Pasteur Institute, and has completed postdoctoral fellowships at St Mary’s hospital in London and Harvard Medical School. His involvement with HIV began in 1983, when, as a young clinical immunologist, he treated a French couple who had returned from Africa with unexplained fever and severe immune deficiency. By 1985, he had started a clinic in Paris specializing in AIDS – which now treats over 1,600 people – and later opened the first night clinic for people with HIV in Paris, enabling them to obtain confidential health care outside working hours.

Dr Kazatchkine was Professor of Immunology at Université René Descartes and Head of the Immunology Unit of the Georges Pompidou Hospital in Paris. He has authored or co-authored of over 500 articles in peer reviewed journals, focusing on auto-immunity, immuno-intervention and pathogenesis of HIV/AIDS.

In addition to his clinical teaching and research activities, Dr. Kazatchkine has played key roles in various organizations, serving as Director of the National Agency for Research on AIDS (ANRS) in France (1998-2005), Chair of the World Health Organization’s Strategic and Technical Advisory Committee on HIV/AIDS (2004-2007), member of the WHO’s Scientific and Technical Advisory Group on tuberculosis (2004-2007), and French Ambassador on HIV/AIDS and communicable diseases (2005-2007). Dr Kazatchkine’s involvement with the Global Fund to Fight AIDS, Tuberculosis and Malaria began when the organization was established in 2001. He was the first Chair of the Global Fund’s Technical Review Panel (2002-2005) and has served as a Board member and Vice-Chair of the Board (2005-2006).


Philippe Lucas has a Masters degree in Studies in Policy and Practice from the University of Victoria and is a PhD student at the University of Victoria’s Social Dimensions of Health program.  He is a Research Affiliate with the Center for Addictions Research of British Columbia and a founding Board member of the Multidisciplinary Association of Psychedelic Studies Canada and the Canadian Drug Policy Coalition.  His scientific research interests, projects and publications include the therapeutic use of cannabis, Canadian and international cannabis policy, and the use of cannabis, ibogaine, and ayahuasca in the treatment of addiction.  Currently, he is a Primary or Co-Investigator on a number of studies examining cannabis substitution theory. In 1999 Philippe founded the Vancouver Island Compassion Society, one of Canada’s longest running non-profit medical cannabis dispensaries, for which he acted as Executive Director until 2009.

Over the years, Philippe has received a number of accolades and awards for his work in the community and academic achievements, including the Queen Elizabeth II Diamond Jubilee Medal (2013), the CRFAIR 2012 Food and Agriculture Champion Award, The Land Conservancy Top 50 BC Environmental Heroes 2011, the University of Victoria Blue and Gold Award for academic excellence and community service (2007), and the Vancouver Island Civil Liberties Association Leadership Award (2002).


A sociologist and advisor for treatment of drug dependency, former Head of Unit of Federal Drug Commissioner of the Ministry of Health, Germany, Dr. Michels has served as Head of the Drugs and Prison projects department of the German AIDS-Hilfe in Berlin, as Drug Commissioner of the Federal State of Bremen, Germany, and as Head of the Office of the Federal Drug Commissioner, Federal Ministry of Health in Berlin, Germany. 

In 2007 he worked as a Consultant for the German International Development Organization GTZ (Gesellschaft für Technische Zusammenarbeit – Association for Technical Cooperation) on “HIV prevention among injecting drug users through harm reduction capacity building and advocacy” in Vietnam, Ukraine and Pakistan. Dr. Michels has published widely in international journals on substance use.


As a founding member of the Czech Medical Academy, he was its first vice-chair and now serves as its chair. Vice-Dean Emeritus of the Third Faculty of Medicine, Charles University in Prague. In 1982–2009, he was the head of the Department of Normal, Pathological, and Clinical Physiology of the Third Faculty of Medicine, Charles University in Prague, and he is a Teaching Professor of physiology and pathological physiology there. He co-established the system of postgraduate studies at Charles University and the Czech Neuropsychopharmacological Society. He has been honored, inter alia, by the award of a Chevalier Des Palmes Academiques by the French Prime Minister. He is a professor of normal and pathological physiology. He is involved in ontogenetical neurophysiology, physiology of talamocortical relations and also physiology of pain and its treatment. He was awarded the title of Professor of Normal and Pathological Physiology in 1991 and from 1990-1996, he was dean of the 3rd Medical Faculty of Charles University.

Registration Needs updating Register Now


Registration Cost
Early Registration

Late Registration From: 2017-09-14 To: 0--
On site Registration
Non Member
Student / Trainee

Group Registrations:

Group registrations not allowed

Accompanying Persons:

Accompanying persons not allowed

Registration Documents:
Letter of invitation:
We don’t provide letter of invitation
Letter of confirmation:
We don’t provide Letter of Confirmation
Proof of professional / educational status:
We don’t need Proof of professional/educational status
Online Abstract Submission:

We don’t accept Online Abstracts

For Book Your Hotel use this link
Scientific Content Up to Date
Submission Info

​​Participants interested in presenting an oral or poster presentation are invited to submit an abstract. All abstracts will undergo peer review by the Scientific Programme Committee and may be accepted for oral or poster presentation.


ORAL – refers to abstracts accepted for oral presentation at the podium in dedicated Oral Presentation Sessions. 

POSTER – poster board presentation in the Poster Area with poster viewing times during breaks. 


Only abstracts submitted via the online submission form will be sent to the Abstract Review Committee for review. Abstracts submitted by fax or e-mail will not be accepted. 

Please do not submit multiple copies of the same abstract.

The Scientific Programme Committee will endeavor to schedule abstracts according to authors' preferences but reserves the right to decide on the final form of presentation.

You will receive confirmation that your abstract has been received, indicating the abstract number which it has been allocated. Please refer to this abstract number in all correspondence regarding the abstract. Please contact the Secretariat if you have not received confirmation that your abstract has been received.

All abstracts will be forw​arded to the Scientific Programme Committee for review. Notifications regarding status will be sent once the review process is complete.​​

Abstracts may be edited by the Scientific Programme Committee before publication online and in the Journal of the Neurological Sciences.​​

The presenting author is expected to attend and register for the ICMCC Congress by the communicated registration deadline and present the poster or oral presentation. One person may only present up to two abstrac​ts at the Congress, but may be a co-author of more.

​Th​e presenting author is required​ to ensure that all co-authors are aware of the content of the abstract before submission of his/her abstract.​​​​

​Abstracts may be accepted for presentation at the Congress, but not for publication in the Journal. ​ ​​

​​Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.


All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university scientific publications office (or other similar facility) or by a copy editor, prior to submission.

Abstracts that have been published or presented prior to this Congress may not be submitted.

Before submitting the abstract, the Abstract Submitter will be required to confirm the following:

1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.

2. Submission of the abstract constitutes my consent to publication (e.g. Congress website, programmes, other promotions, etc.)

3. The abstract submitter warrants and represents that he/she is the sole owner or has the rights of all the information and content ("Content") provided to ICMCC Congress (Hereafter: "The Organizers"). The publication of the abstract does not infringe any third party rights including, but not limited to, intellectual property rights. The abstract submitter grants the Organizers a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the content.

4. The Organizers reserve the right to remove from any publication an abstract which does not comply with the above.

5. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.​​


Before you begin, please prepare the following information:

Presenting author's contact details - 

​​Email address

​Full first and family name(s).

Affiliation details: department, institution / hospital, city, state (if relevant), country​

​​Co-a​​uthors' contact details - 

​​Email address

​Full first and family name(s).

Affiliation details: department, institution / hospital, city, state (if relevant), country​

​​Abstract title - limited to 25 words in UPPER CASE 

​​Abstract text – limited to 250 words (​We recommend using word-processing software (for example, Word) for editing your abstract and counting the number of words.)​

​Graphs and images – You can upload graphs and images in JPG, PNG and GIF format only. When including a table, it is recommended to save the table as an image and then upload it to the abstract.​ A maximum of 3 tables/graphs/images can be included per abstract.

After you submit your abstract, you can re-enter the submission link at any time to view and edit your abstract until the deadline date. Submitted abstracts cannot be modified or corrected after the submission deadline. There is no option to save the abstract as draft and to submit it at a later stage. If you do not submit your abstract, the information will be deleted.​​

Abstract submission deadline 2017-08-19
Sponsors Exhibitors
General Info

Please contact me for additional information, pricing and booking form:

Frederiek Strating

Industry Liaison and Sales Associate

Tel:  +31 20 763 0512


Sponsors / Supporters

Space Allocation will be made on a “first come, first served” basis. A completed Exhibition Booking Form and Contract must be faxed / emailed to ensure reservation of a desired location. Upon receipt of the Exhibition Booking Form and Contract, space will be confirmed and an invoice will be sent. Please note that three alternative booth choices should be clearly indicated on the application form. Space allocations will be made in the order in which application forms with payment are received.



All exhibitors are required to be registered and will receive a badge displaying the exhibiting company name. Two exhibitor badges will be given by booking a High Counter. Any additional exhibitors will be charged an exhibitor registration fee. 

Exhibitor registrations allow access to the exhibition area only and shall be used by company staff only. An exhibitor registration form will be included in the Exhibitor’s Manual.



An Exhibitors’ Technical Manual outlining all technical aspects of exhibiting will be available approximately 3 month prior to the Conference. It will include the following:

Technical details about the Venue

Final exhibition details and information

Contractor details

Services available to exhibitors and order forms



Please note that all materials entering the venue incur a handling charge. This includes materials for inserts and display.

In order to receive a price quote for handling and to assure arrival of your materials, please be sure to complete the “Pre-Advise” form included in the shipping instructions when you receive either the Exhibition or Symposia ​Technical Manuals.



Exhibitors and Supporters are welcome to visit the Conference venue at their convenience. Please contact the

venue directly to arrange this.



You can submit your logo and company's profile, read important exhibitor information and complete orders for your stand on the Kenes Exhibitors' Portal. The Exhibition Manager will contact you with the link to the Exhibitors' Portal, including your personal login details.​


The Terms and Conditions of exhibiting are included in the Online Prospectus. Please note that signing of the BOOKING

FORM AND CONTRACT indicates acceptance of these Terms and Conditions. The Exhibition Booking Form will be held as a valid liable contract, by which both parties will be bound. An exclusive handling agent will be designated to the International Conference on Medical Cannabis & Cannabinoids. ​​The exclusivity of an agent for the handling needs of congresses refers specifically to work inside the venue. Exhibitors may use their own couriers up to the venue door and from outside of the venue door at the end of the conference. This organizational decision has been made for the safety and efficiency benefits to exhibitors and for the successful flow of the conference.

Organising Agency

Josh Margo , Mr , Kenes Group

Phone: 011-972-3-972-7450


Event map
Revelant Events